How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,797 results for

Urine Uric Acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Surgical Management of Stones: AUA/Endourology Society Guideline

or distal ureteral stones who require intervention (who were not candidates for or who failed MET), clinicians should recommend URS as first-line therapy. For patients who decline URS, clinicians should offer SWL. (Index Patients 2,3,5,6) Strong Recommendation; Evidence Level Grade B 12. URS is recommended for patients with suspected cystine or uric acid ureteral stones who fail MET or desire intervention. Expert Opinion 13. Routine stenting should not be performed in patients undergoing SWL. (Index (...) ' published in 2014. 6 The surgical management of patients with various stones is described below and divided into 13 respective patient profiles. Index Patients 1-10 are non-morbidly obese; non-pregnant adults (≥ 18 years of age) with stones not thought to be composed of uric acid or cystine; normal renal, coagulation and platelet function; normally positioned kidneys; intact lower urinary tracts without ectopic ureters; no evidence of sepsis; and no anatomic or functional obstruction distal to the stone

2016 American Urological Association

282. Screening and Management of Lipids

- treated patients results in a reduction in the risk of cardiovascular events. Therefore niacin should not be used in conjunction with statins for reduction in cardiovascular events. Rare cases of rhabdomyolysis have been associated with concomitant use of statins and niacin in doses > 1 g. Niacin patients should have baseline ALT and glucose and uric acid, with follow up ALT at 3 months or at dose escalations, and periodically thereafter. Niacin is available over the counter (OTC) as a dietary (...) controlled trials; B=controlled trials, no randomization; C=observational trials; D=opinion of expert panel. 2 UMHS Lipid Therapy Guideline, May 2014 Table 1. Secondary Causes of Hyperlipidemia Secondary Cause Elevated LDL-C Elevated Triglycerides Diet Saturated or trans fats, weight gain, anorexia Weight gain, very low-fat diets, high intake of refined carbohydrates, excessive alcohol intake Drugs Diuretics, cyclosporine, glucocorticoids, amiodarone Oral estrogens, glucocorticoids, bile acid

2016 University of Michigan Health System

284. Reasanz - serelaxin

4/112 List of abbreviations AA Aldosterone antagonists ACE Angiotensin converting enzyme AE Adverse event AHF Acute Heart Failure AR Assessment report ARB Angiotensin receptor blocker Asp Aspartate, Aspartic acid AUC Area under the concentration-time curve AUC0-t AUCinf BET Area under the serum concentration-time curve from time zero to time t, using the linear trapezoidal rule. Concentrations below the LLOQ are set to zero and therefore excluded from the calculation. Actual sample collection (...) P450 DBP Diastolic Blood Pressure DDI Drug-drug interactions DNA Deoxyribonucleic acid DO Dissolved oxygen DP Drug product DRE Disease-related event DS Drug substance E. coli Escherichia coli ECG Electrocardiogram eGFR Estimated glomerular filtration rate ELISA Enzyme-linked immunosorbent assay EMA European Medicines Agency ERK1/2 Extracellular-signal-regulated kinases ET Endothelin ET-1 Endothelin isoform 1 ETA Endothelial endothelin type A receptor ETB Endothelial endothelin type B receptor FDA

2014 European Medicines Agency - EPARs

285. Deltyba - delamanid

Balance 132 7. Recommendations following re-examination 136 Assessment report EMA/CHMP/125521/2013 Page 3/140 List of abbreviations E Adverse event FB Acid-fast bacilli PTT Activated partial thromboplastin time UC Area under the concentration-time curve ID Twice daily DISC Clinical Data Interchange Standards Consortium FU Colony forming units HMP Committee for Medicinal Products for Human Use L Total body clearance of drug from plasma max Maximum drug concentration LT Dose-limiting toxicity M Drug (...) and the majority of the safety pharmacology studies conducted by the applicant were reported to be GLP compliant. The safety studies that were not conducted to GLP were conducted to an appropriate scientific standard. 2.3.2. Pharmacology Primary pharmacodynamic studies The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid. This is observed at lower IC 50 values than that of isoniazid (INH). However

2014 European Medicines Agency - EPARs

287. Dapagliflozin (Farxiga)

and insulin analogues, meglitinides and sulfonylureas (SU) may be associated with hypoglycemia and weight gain. Amylin mimetics, alpha-glucosidase inhibitors, biguanides, bile acid sequestrants, and GLP-1 receptor agonists may be associated with intolerable gastrointestinal side effects, and pancreatitis and allergic reactions have been reported with dipeptidyl peptidase-4 [DPP4] inhibitors and GLP-1 receptor agonists. Further, progressive ß-cell dysfunction may lead to secondary treatment failure (...) in the kidney, dapagliflozin reduces renal glucose reabsorption, resulting in glycuresis over a 24-hour Reference ID: 3426720Clinical Review Frank Pucino, PharmD, MPH NDA 202293; FARXIGA (dapagliflozin) 24 dosing interval. Dapagliflozin does not inhibit other glucose transporters important for glucose transport in the gut (e.g., SGLT1) and peripheral tissues. 4.4.2 Pharmacodynamics In patients with T2DM, approximately 70 grams of glucose may be excreted in the urine per day following 10 mg daily doses

2014 FDA - Drug Approval Package

288. Sonidegib (Odomzo)

have been exposed to ODOMZO during pregnancy, either directly or through seminal fluid, to contact the Novartis Pharmaceuticals Corporation at 1-888-669-6682. Blood Donation ? Advise patients not to donate blood or blood products while taking ODOMZO and for 20 months after stopping treatment. Musculoskeletal Adverse Reactions Advise patients to contact their healthcare provider immediately for new or worsening signs or symptoms of muscle toxicity, dark urine, decreased urine output (...) , or the inability to urinate [see Warnings and Precautions (5.2)]. Administration Instructions Advise patients to take ODOMZO on an empty stomach, at least 1 hour before or 2 hours after a meal [see Dosage and Administration (2.1)]. Lactation Advise women not to breastfeed during treatment with ODOMZO and for up to 20 months after the last dose [see Use in Specific Populations (8.2)]. Reference ID: 3796270

2014 FDA - Drug Approval Package

289. Prevention of Recurrent Kidney Stones

with residual or recurrent struvite stones in whom surgical options have been exhausted, AUA cites acetohydroxamic acid as a treatment option. AUA recommends potassium citrate for patients with uric acid and cystine stones in order to raise urinary pH to an optimal level. Prevention of Recurrent Kidney Stones ACP (2014) Recommendation 1 : The ACP recommends management with increased fluid intake spread throughout the day to achieve at least 2 L of urine per day to prevent recurrent nephrolithiasis. ( Grade (...) animal protein. ( Expert Opinion ) Clinicians should counsel patients with uric acid stones or calcium stones and relatively high urinary uric acid to limit intake of non-dairy animal protein. ( Expert Opinion ) Clinicians should counsel patients with cystine stones to limit sodium and protein intake. ( Expert Opinion ) Pharmacologic Therapies Clinicians should offer thiazide diuretics to patients with high or relatively high urine calcium and recurrent calcium stones. ( Standard; Evidence Strength

2015 National Guideline Clearinghouse (partial archive)

290. Urolithiasis

characteristics may provide information on the type of stone. Oral chemolitholysis is based on alkalinisation of urine by application of alkaline citrate or sodium bicarbonate [78, 80]. The pH should be adjusted to 7.0-7,2. Within this range, chemolysis is more effective at a higher pH, which might lead to calcium phosphate stone formation. Monitoring of radiolucent stones during therapy is the domain of US, however, repeat NCCT might be necessary. In the case of uric acid obstruction of the collecting system (...) related to calcium stones 44 4.6.1 Hyperparathyroidism 44 4.6.2 Granulomatous diseases 45 4.6.3 Primary hyperoxaluria 45 4.6.4 Enteric hyperoxaluria 45 4.6.5 Renal tubular acidosis 45 4.6.6 Nephrocalcinosis 47 4.6.6.1 Diagnosis 47 4.7 Uric acid and ammonium urate stones 47 4.7.1 Diagnosis 47 4.7.2 Interpretation of results 47 4.7.3 Specific treatment 48 4.8 Struvite and infection stones 48 4.8.1 Diagnosis 48 4.8.2 Specific treatment 49 4.8.3 Recommendations for therapeutic measures of infection stones

2015 European Association of Urology

291. Paediatric Urology

Subureteric injection of bulking materials 47 3M.3.2.2 Open surgical techniques 48 3M.3.2.3 Laparoscopy 48 3M.3.3 Recommendations for the management of vesicoureteric reflux in childhood 49 3N URINARY STONE DISEASE 51 3N.1 Epidemiology, aetiology and pathophysiology 51 3N.2 Classification systems 51 3N.2.1 Calcium stones 51 3N.2.2 Uric acid stones 52 3N.2.3 Cystine stones 53 3N.2.4 Infection stones (struvite stones) 53 3N.3 Diagnostic evaluation 53 3N.3.1 Imaging 55 3N.3.2 Metabolic evaluation 55 3N.4 (...) Recommendations for the treatment of acute scrotum in children 15 3E HYPOSPADIAS 15 3E.1 Epidemiology, aetiology and pathophysiology 15 3E.1.1 Risk factors 15 3E.2 Classification systems 15 3E.3 Diagnostic evaluation 16 3E.4 Disease management 16 3E.4.1 Age at surgery 16 3E.4.2 Penile curvature 17 3E.4.3 Preservation of the well-vascularised urethral plate 17 3E.4.4 Re-do hypospadias repairs 17 3E.4.5 Urethral reconstruction 18 3E.4.6 Urine drainage and wound dressing 18 3E.4.7 Outcome 18 3E.5 Follow-up 19 3E

2015 European Association of Urology

294. Treatment Strategies for Patients with Renal Colic

Treatment Strategies for Patients with Renal Colic TITLE: Treatment Strategies for Patients with Renal Colic: A Review of the Comparative Clinical and Cost-Effectiveness DATE: 17 November 2014 CONTEXT AND POLICY ISSUES Urinary track calculi or urinary stones, formed from crystalized chemicals in the urine such as calcium oxalate, uric acid and cystine, occur in one of ten Canadians in their lifetime. 1 The obstruction of the urinary tract by calculi at the narrowest anatomical areas leads

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

295. Topiloric/Uriadec (topiroxostat)

for the indications and dosage and administration as shown below. [Indication] Gout, hyperuricaemia [Dosage and administration] The usual adult initial dosage is 20 mg/dose of topiroxostat orally administered twice daily in the morning and evening. Thereafter, the dose should be gradually increased, as needed, while monitoring blood uric acid levels. The usual maintenance dosage should be 60 mg/dose twice daily. The dose may be adjusted according to the patient’s condition, up to 80 mg/dose twice daily. 4 Review (...) of topiroxostat orally administered twice daily in the morning and evening. Thereafter, the dosage should be gradually increased, as needed, while monitoring blood uric acid levels. The usual maintenance dosage should be 60 mg/dose twice daily. The dose may be adjusted according to the patient’s condition, up to 80 mg/dose twice daily. II. Summary of the Submitted Data and Outline of Review by the Pharmaceuticals and Medical Devices Agency (PMDA) A summary of the submitted data and an outline of the review

2013 Pharmaceuticals and Medical Devices Agency, Japan

296. Acofide (acotiamide hydrochloride hydrate)

burning; and there is no evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms.” The cause of FD is not fully elucidated. The current assumption is that the symptoms are caused by the involvement of multiple factors including abnormal gastric emptying, gastric dysrhythmia, gastric hypersensitivity, hypersensitivity and motility disorder of the small intestine, impaired postprandial relaxation of the gastric fundus, vagus nerve disorder, enhanced acid (...) by elementary analysis, ultraviolet spectroscopy, infrared spectrophotometry (IR), water content, hydrochloric acid content, nuclear magnetic resonance spectrometry ( 1 H-, 13 C-NMR), mass spectrometry, and X-ray crystallography. 2.A.(1).2) Manufacturing process The drug substance is manufactured using ***************************************, ********************************, and ***************************** as the starting materials through ** **** processes and ** **** processes. The processes

2013 Pharmaceuticals and Medical Devices Agency, Japan

297. Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports. Full Text available with Trip Pro

after benzbromarone administration. Ultrasound showed multiple small stones in both kidneys, and the 24-hour urine uric acid level was 3128 mg. In case 2, a 17-year-old male student presented with AKI after self-administration of 50 mg of benzbromarone. His Scr increased to 6.8 mg/dL on day 3 after benzbromarone administration. Ultrasound showed multiple stones in the left kidney.Both patients underwent renal biopsy, with findings of acute tubular interstitial nephropathy in case 1 and acute tubular

2019 Medicine

298. High-Resistant Starch, Low-Protein Flour Intervention on Patients With Early Type 2 Diabetic Nephropathy: A Randomized Trial. (Abstract)

); however, it did not change the interleukin-6 and Tumor Necrosis Factor α (TNF-α) concentration.Twelve-week intervention with high-RS, low-protein flour improved the blood glucose and blood lipid levels, decreased the serum uric acid (UA) and urine β2-MG, and enhanced the ability to prevent antioxidative stress in patients with early DN.Copyright © 2018. Published by Elsevier Inc. (...) flour intake led to a significant reduction in fasting blood glucose, HbA1c, total cholesterol, and triglycerides levels (P < .05 for all). The changes in serum uric acid (UA) and β2-microglobulin (β2-MG) level were observed after high-RS, low-protein flour intervention (uric acid [mean ± standard deviation]: -24.7 ± 38.5 μmol/L, P = .001; β2-MG: 0.5 ± 0.9 mg/L, P = 0.018). In addition, high-RS, low-protein flour intake increased serum superoxide dismutase level by 10.1 ± 27.7 U/mL (P < .05

2019 Journal of Renal Nutrition Controlled trial quality: uncertain

299. Hyperuricemia and its related histopathological features on renal biopsy. Full Text available with Trip Pro

at the time of the kidney biopsy were collected from Renal Treatment System (RTS) database, including age, gender, serum uric acid (UA), glomerular filtration rate (eGFR), serum creatinine (Cr), urea, albumin (Alb), 24 h urine protein quantitation (24 h-u-pro) and blood pressure (BP). Pathological morphological changes were evaluated by two pathologists independently. Statistical analysis was done using SPSS 21.0.Among 1070 patients, 429 had IgA nephropathy (IgAN), 641 had non-IgAN. The incidence of HUA (...) Hyperuricemia and its related histopathological features on renal biopsy. Hyperuricemia (HUA) is very common in chronic kidney disease (CKD). HUA is associated with an increased risk of cardiovascular events and accelerates the progression of CKD. Our study aimed to explore the relationship between baseline serum uric acid levels and renal histopathological features.One thousand seventy patients receiving renal biopsy in our center were involved in our study. The baseline characteristics

2019 BMC Nephrology

300. Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients. Full Text available with Trip Pro

Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients. A study to evaluate the prevalence of uric acid (UA) nephrolithiasis with dual-energy CT (DECT) and explore the risk factors for kidney stones in primary gout patients.Eighty-four consecutive gout patients underwent urinary tract ultrasonography or DECT to confirm the existence of kidney stones. Urine and blood samples were also taken for laboratory analysis.Forty-one subjects (48.8 (...) %) patients presented hypomagnesuria. Forty-three (51.8%) patients had low urine volume. Unduly acidic urine (UAU) was present in 36 patients (44.4%). Hyperuricosuria was only found in ten (12.2%) patients. In comparison to the non-lithiasic group, the lithiasic group was more likely to have a UAU. Binary logistic regression showed that female gender was a protective factor, while disease duration of gout and low urine pH were risk factors for nephrolithiasis.Our results indicated that nephrolithiasis

2019 BMC Nephrology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>